Email Updates

You are here

Home

26 OCTOBER 2018 VOLUME 19 ISSUE 43

Media Coverage

  • Vaginal Rings, Films, Inserts or Gels – It’s All About Choice

    There is no single HIV prevention technology which suits everyone – young African women who have tried four different vaginal products make different choices, with no one product being much more popular than the others, researchers told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid this week.

    October 26, 2018
    Combination Prevention, Microbicides
    aidsmap

  • Tax on drinks to raise funds for HIV treatment in Uganda

    The government believes $2.5m a year will be generated from the 2 percent total tax levies collected from drinks, including beer, spirits and waragi, a local liquor, which will be channelled into a new HIV and AIDS trust fund (ATF).

    October 26, 2018
    Treatment
    The Guardian

  • Scientists 'Far from Discovering' HIV Cure

    The ability of the HIV virus to mutate all the time is proving to be the most outstanding stumbling block for scientists to get the much-awaited HIV cure, researcher Dr Zaza Ndhlovu, Africa Health Research Institute, South Africa has said.

    October 26, 2018
    Cure
    The Observer

  • Kenya wins accolades for effective HIV fight

    Kenya's HIV prevention strategies are among the best and most workable in Africa, a global forum says.

    October 25, 2018
    General
    Daily Nation

  • The Long Tail of Injectable PrEP is Especially Long for Women

    Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around 18 months after their last injection, Raphael Landovitz of the University of California told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid yesterday. While providing evidence of the durability and potency of injectable cabotegravir, the findings raise concerns about the potential development of drug resistance.

    October 25, 2018
    PrEP
    aidsmap

  • Zim-born HIV researcher scoops Desmond Tutu award

    The award, named in honour of outspoken South African cleric Desmond Tutu, who is one of the leading global advocates for HIV prevention and the dignity of all people, is presented every two years to an individual or organisation that has worked in an outstanding manner to advance both HIV prevention research and the human rights of people affected by HIV.

    October 25, 2018
    General
    NewsDay

  • Will bNAbs Yield a One Size Fits all HIV Vaccine?

    It has been 21 years now and still ongoing—research for the HIV vaccine. Researchers are now focusing on identifying a particular antibody type that can disarm the virus, by using the broadly neutralizing antibodies (bNAbs).

    October 25, 2018
    Antibody Related Research, HIV Vaccine
    New Vision

  • Why it’s hard to find the vaccine

    “It’s a scientific problem,” Anthony Fauci, an American immunologist who has made substantial contributions to HIV/AIDS research and other immune-deficiencies, both as a scientist and as the head of the National Institute of Allergy and Infectious Diseases told New Vision.

    October 25, 2018
    HIV Vaccine
    New Vision

  • More prevention research needed to control the HIV/AIDS pandemic

    As scientific research continues to advance, experts in health care continue to discuss potential timelines for an HIV vaccine or an HIV cure, but HIV elimination and even further, eradication, are also on the minds of many.

    October 25, 2018
    General
    Contagion Live

  • Far more people may be using PrEP than we know, HIV prevention conference hears

    Many more gay men and men who have sex with men (MSM) may be using pre-exposure prophylaxis (PrEP) than figures from demonstration projects and national rollouts suggest, Michelle Rodolph, technical officer for the World Health Organization, told the HIVR4P 2018 conference in Madrid in Spain.

    October 24, 2018
    PrEP
    aidsmap

  • HIV prevention: Bridging the gap between research and impact

    "It is not just about R&D but about R&D and D — research and development, and delivery. If you take anyone of those three letters out, we fail. Each of them is equally important."

    October 24, 2018
    General
    Citizen News Service

  • A Buffet of Choices for HIV Prevention

    In fact a 2017 report by UNAIDS put the number of new infections at 1.8 million globally. The simple explanation for this is that the “One size fits all” doesn’t work with HIV prevention. Now, researchers attending the HIV Research for Prevention conference 2018 in Madrid, Spain have today, Oct.24 shared findings from studies they are undertaking to explore new avenues through which people can protect themselves from getting infected.

    October 24, 2018
    Combination Prevention, General, Microbicides, Multipurpose Prevention Technologies
    Independent

  • Successful trial of quadrivalent mosaic HIV vaccine paves way for larger study in Southern Africa

    A quadrivalent mosaic HIV vaccine induced greater immune responses on a variety of assays and against several HIV clades than its trivalent equivalent, Daniel J. Stieh, Ph.D., of Janssen Vaccines & Prevention BV reported at the HIVR4P conference in Madrid, Spain. This quadrivalent version will be used in future vaccine studies, he added.

    October 24, 2018
    HIV Vaccine
    The BodyPro

  • Viral suppression within three months of HIV diagnosis should be a policy target, NYC officials say

    An undetectable viral load within three months of HIV diagnosis should be added as a target to the US National HIV/AIDS Strategy, public health officials from New York City argue in The Journal of Infectious Diseases. They showed that improvement in this target is feasible, with the proportion of people virally suppressed within three months of diagnosis increasing from 9 percent in 2007 to 39 percent in 2016.

    October 23, 2018
    Treatment
    aidsmap

  • High hopes for advanced HIV trials

    The precedent-setting Antibody Mediated Prevention (AMP) Studies - the most advanced clinical trials to test whether an antibody can prevent HIV infection in people - are fully enrolled.

    October 23, 2018
    Antibody Related Research
    IOL

  • Global HIV prevention conference kicks off in Spain

    Dubbed HIV Research for Prevention (HIVR4P) 2018, the week long event which happens every two years will focus on several new prevention innovations. The new innovations are Pre-Exposure Prophylaxis (PrEP) which involves giving HIV drugs to negative people at risk of infection as prevention, progress on the search for the vaccine, treatment as prevention and microbicides such as the ARV laced vaginal ring, implants among others.

    October 23, 2018
    General
    Independent

  • HCV increases mortality of people with HIV despite antiretroviral treatment

    Hepatitis C virus (HCV) increases mortality of persons with HIV despite antiretroviral treatment but is associated with less harm when treated with direct-acting antivirals (DAAs), according to a 10-year follow-up study.

    October 23, 2018
    Treatment
    MD Magazine

  • 300,000 people on PrEP globally, mostly in the USA and Africa

    At least 309,525 people have started to take pre-exposure prophylaxis (PrEP) in 68 countries, but 71 percent of PrEP users are in North America, according to a global analysis presented to the HIVR4P conference in Madrid.

    October 23, 2018
    PrEP
    aidsmap

  • HIV activists take to the stage at 'Research 4 Prevention' opening to demand continued funding of wider prevention research agenda

    Just before Tony Fauci, M.D., director of the NIH's National Institute of Allergies and Infectious Diseases (NIAID) took the stage to deliver his address to the crowd, several dozen people filed on the stage with signs that read: "Whose choice, our choice?" and "Dear NIAID, Fund Microbicides NOW!"

    October 23, 2018
    Microbicides
    The Body

  • HIV vaccine experts sketch road map for research

    Key goals outlined in the plan include: speeding the research pipeline by optimizing the development of experimental HIV vaccines; developing a plan for how best to translate a successful vaccine trial into action, yielding a widely available vaccine; and keeping the research ball rolling by recruiting financial and brainpower resources from a diverse field.

    October 23, 2018
    HIV Vaccine
    POZ

  • Truvada and the truth: is HIV prevention propelling the STI epidemic?

    In the US, public health officials are beginning to credit Truvada with pushing down HIV transmission rates. An estimated 180,000 Americans use PrEP, the vast majority of them MSM.

    October 21, 2018
    The Guardian

  • CDC encourages health care providers to “Prescribe HIV Prevention”

    Our nation’s federal health agency has a message for health care providers: Prescribe HIV prevention. In fact, the Centers for Disease Control and Prevention (CDC) launched a new initiative titled exactly that: “Prescribe HIV Prevention.”

    October 18, 2018
    PrEP
    POZ

  • Wide Range of Views About Switching to Weekly, Monthly or Biannual ART

    Two-thirds of people taking combination antiretroviral therapy (cART) would be interested in switching to a once-weekly oral regimen should it become available, according to American research published in Open Forum Infectious Diseases. Opinion was evenly split on switching to injectable therapy but treatment delivered using implants attracted relatively little interest.

    October 15, 2018
    Treatment
    aidsmap

Published Research

Announcements